In vitro activity of a new antibacterial rhodanine derivative against Staphylococcus epidermidis biofilms.
OBJECTIVE
Staphylococcus epidermidis biofilms form at the surface of implants and prostheses and are responsible for the failure of many antibiotic therapies. Only a few antibiotics are relatively active against biofilms, and rifampicin, a transcription inhibitor, is among the most effective molecules for treating biofilm-related infections. Having recently selected a new potential transcription inhibitor, we attempted to evaluate its efficacy against S. epidermidis biofilms.


METHODS
Biofilm-forming S. epidermidis strains were grown planktonically or as biofilms and their susceptibility to this transcription inhibitor was compared with reference antibiotics with different mechanisms of action.


CONCLUSIONS
Our results demonstrate that this new molecule is active; its effects are fast and kinetically related to those of rifampicin, but unlike rifampicin it does not select for resistant bacteria.
Gualtieri
Maxime
M
CNRS UMR 5160, Centre de Pharmacologie et Biotechnologie pour la Santé, Faculté de Pharmacie Montpellier, France.
Bastide
Lionel
L
Villain-Guillot
Philippe
P
Michaux-Charachon
Sylvie
S
Latouche
Jaqueline
J
Leonetti
Jean-Paul
JP
D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000494:pharmacology*; D018441:Biofilms / Q000187:drug effects* / Q000254:growth & development; D012321:DNA-Directed RNA Polymerases / Q000037:antagonists & inhibitors*; D006801:Humans; D008826:Microbial Sensitivity Tests; D011137:Polystyrenes; D012236:Rhodanine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D012293:Rifampin / Q000494:pharmacology; D013212:Staphylococcus epidermidis / Q000187:drug effects* / Q000254:growth & development; D014158:Transcription, Genetic / Q000187:drug effects
D000900:Anti-Bacterial Agents; D011137:Polystyrenes; D012236:Rhodanine; D012321:DNA-Directed RNA Polymerases; D012293:Rifampin